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Abstract
Introduction: Obesity and prostate cancer are related, but the causal relationship remains unknown. The aim of the study was to compare 
concentrations of leptin, adiponectin and chemerin in patients with prostate cancer and benign prostate hyperplasia and to examine as-
sociations of the adipokines with the grade of prostate cancer, interleukin-6 (IL-6), insulin resistance and anthropometric and metabolic 
variables. 
Material and methods: The study group consisted of 140 men divided into two groups: I- prostate cancer (n = 74) and II — with benign 
hyperplasia (n = 66). Serum leptin, adiponectin, chemerin, IL-6 and metabolic profile were measured. Considering histological differentia-
tion prostate cancer patients were divided into 3 subgroups: well differentiated (Gleason score ≤ 6), moderately differentiated subgroup 
(Gleason 7), and poorly differentiated (Gleason ≥ 8).
Results: There were no differences between groups in BMI, waist circumference, HOMA-I, serum levels of total cholesterol, glucose, tri-
glycerides, adiponectin, leptin and chemerin. However, the concentrations of PSA, IL-6 and leptin-to-adiponectin ratio were significantly 
higher in cancer group compared with benign hyperplasia group. In the poorly differentiated cancer subgroup, subjects had higher PSA, 
leptin, chemerin, IL-6 and triglycerides concentrations as well as higher leptin-to-adiponectin ratio. Overweight and obese men with 
prostate cancer were more likely to have moderately or poorly differentiated cancer. In the all men serum adiponectin was significantly 
correlated with HOMA-I, BMI, glucose, triglycerides, cHDL. There were significant correlations between leptin and BMI, HOMA-I, waist 
circumference, glucose, triglycerides and cHDL. Among all the participants we observed associations between chemerin and waist, 
triglycerides and leptin-to-adiponectin ratio. In prostate cancer patients chemerin correlated with IL-6 and leptin as well as with leptin-
to-adiponectin ratio. We measured significant positive correlations between Gleason score and chemerin, leptin concentrations and 
leptin-to-adiponectin ratio. There were positive correlations between adiponectin and PSA levels in cancer group, as well as in all men.
Conclusions: Leptin-to-adiponectin ratio and IL-6 concentration were elevated in men with prostate cancer. Leptin, chemerin, IL-6 and 
leptin-to-adiponectin ratio were associated with Gleason score. In prostate cancer men the relationships between serum leptin, chemerin, 
IL-6 and leptin-to-adiponectin ratio were dependent on each other. Overweight and obese men with prostate cancer had a higher Gleason 
score. (Endokrynol Pol 2018; 69 (2): 120–127)
Key words: obesity, prostate cancer, adiponectin, leptin, chemerin, interleukin-6
Streszczenie
Wstęp: Nie do końca są poznane mechanizmy wiążące otyłość i raka prostaty. Celem pracy było porównanie stężeń leptyny, adiponektyny 
i chemeryny u pacjentów z rakiem prostaty i łagodnym przerostem prostaty oraz ocena powiązań pomiędzy adipokinami i stopniem 
zróżnicowania Gleasona, interleukiną-6 (IL-6), opornością insulinową oraz antropometrycznymi i metabolicznymi parametrami. 
Materiał i metody: Do badania włączono 140 mężczyzn, których w zależności od wyniku biopsji podzielono na 2 grupy: I z rakiem pro-
staty (n = 74) i II z łagodnym przerostem (n = 66). Oceniano stężenia leptyny, adiponektyny, chemeryny, IL-6 oraz profil metaboliczny. 
Na podstawie wyniku biopsji pacjentów z rakiem prostaty podzielono na 3 podgrupy: rak dobrze zróżnicowany (skala Gleasona ≤ 6), 
rak średnio zróżnicowany (skala Gleasona 7) i rak źle zróżnicowany (skala Gleasona ≥ 8).
Wyniki: Gdy porównano obie grupy nie stwierdzono różnic w BMI, w obwodzie talii, HOMA-I, w stężeniu cholesterolu, glukozy, trójgli-
cerydów, leptyny, adiponektyny i chemeryny. Stężenie PSA, IL-6 oraz wskaźnik leptyna-adiponektyna były istotnie wyższe u mężczyzn 
z rakiem niż z przerostem prostaty. U pacjentów z rakiem o najwyższym stopniu złośliwości występowały wyższe stężenia PSA, leptyny, 
chemeryny, IL-6 i trójglicerydów, wyższy też był wskaźnik leptyna-adiponektyna. U osób z nadwagą i otyłością istotnie częściej wystę-
pował rak średnio lub źle zróżnicowany. U wszystkich badanych stężenie adiponektyny istotnie korelowało z HOMA-I, BMI, glukozą, 
trójglicerydami i cHDL. Stwierdzono korelacje pomiędzy leptyną, BMI, HOMA-I, obwodem w talii, glukozą, trójglicerydami i cHDL. 
Wśród wszystkich badanych obserwowano powiązania pomiędzy chemeryną i obwodem w talii oraz trójglicerydami i wskaźnikiem 
leptyna-adiponektyna. U pacjentów z rakiem prostaty chemeryna korelowała z IL-6 i leptyną a także ze wskaźnikiem leptyna-adipo-
nektyna. Stwierdzono statystycznie istotne powiązania pomiędzy złośliwością raka prostaty ocenianą w skali Gleasona oraz stężeniem 
chemeryny i leptyny oraz wskaźnikiem leptyna-adiponektyna. Dodatnią korelację pomiędzy adiponektyną i PSA wykryto u mężczyzn 
z rakiem prostaty oraz u wszystkich badanych. 
Lucyna Siemińska M.D., Ph.D., Department of Pathophysiology and Endocrinology, School of Medicine with the Division of Densitry in 
Zabrze, Medical University of Silesia, Traugutta St. 2, 41–800 Zabrze, Poland, e-mail: lusiem@poczta.onet.pl
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Wnioski: Wskaźnik leptyna-adiponektyna oraz stężenie IL-6 były wyższe u mężczyzn z rakiem prostaty niż w łagodnym przeroście. 
Leptyna, chemeryna, IL-6 oraz wskaźnik leptyna-adiponektyna były powiązane ze skalą Gleasona. U pacjentów z rakiem prostaty stwier-
dzono wzajemne powiązania między stężeniem chemeryny, leptyny, IL-6 i wskaźnikiem leptyna-adiponektyna. Mężczyzn z nadwagą 
i otyłością charakteryzował niższy stopień zróżnicowania raka oceniany w skali Gleasona. (Endokrynol Pol 2018; 69 (2): 120–127)
Słowa kluczowe: otyłość; rak prostaty; adiponektyna; leptyna; chemeryna; interleukina-6
Introduction
Different factors including age, low physical activity, 
dietary habits and family history favor the development 
of prostate cancer. Obesity or being overweight are 
recognized as a risk factors for prostate cancer [1]. Al-
though the mechanisms underlying those associations 
are not fully recognized, it may be possible that insulin 
resistance, chronic inflammation and excess of adipose 
tissue or/and its dysfunction, known as adiposopathia, 
foster prostate cancerogenesis [2]. Adipokines produced 
by adipose tissue influence in metabolic processes and 
they mediate inflammation, cell proliferation and angio-
genesis. The most abundant adipokines are leptin and 
adiponectin. In obesity, changes in their secretion may 
be associated with cancerogenesis [2]. Leptin serum 
levels are closely correlated with adipose tissue mass. 
The stimulating role of leptin in chronic inflammation, 
neoangiogenesis and tumorigenesis is established. The 
overexpression of leptin and its receptors has been 
well documented in numerous types of cancer [2, 3]. 
Another hormone which is secreted by adipose tissue 
is adiponectin. Various studies have been carried out 
to evaluate the relationships between adiponectin 
and cancerogenesis and most of them have reported 
that hypoadiponectinemia promotes tumor cell pro-
liferation and influences mitogenic growth factors [2]. 
Chemerin is the next newly identified adipokine se-
creted by adipose tissue which may be associated with 
cancerogenesis. To our knowledge, there are no studies 
assessing circulating chemerin levels in patients with 
prostate cancer. Interleukin-6 (IL-6) is another cytokine 
produced by adipose tissue which serum levels are 
increased in obesity. This proinflammatory cytokine 
is involved in cancerogenesis by modulating cellular 
proliferation, invasion and angiogenesis. Previous stu-
dies regarding relationships between IL-6 and prostate 
cancer have reported essential role of this cytokine in 
development and progression of prostate cancer [4, 5].
Large prospective studies [1] reveal that excess body 
adiposity promotes not only cancerogenesis but is also 
associated with increased risk of benign prostate hyper-
plasia. However, in molecular aspect, benign prostate hy-
perplasia and prostate cancer present two separate patho-
physiological pathways and there are no direct relation-
ships between those diseases. The common future of both 
diseases are hormonal dependence, slow progression 
and prostatic inflammation. However, it is not known 
whether links connecting obesity and prostate cancer 
and benign prostate hyperplasia are exactly the same. 
Therefore, the next aim of the study is to compare links 
connecting obesity and adipokines in group of patients 
with prostate cancer and benign prostate hyperplasia. 
The specific goals of the study are:
1. Determining serum concentrations of adipokines: 
leptin, adiponectin, chemerin and inflammatory 
cytokine IL-6 in patients with prostate cancer and 
with benign prostate hyperplasia.
2. Evaluating associations between adipokines and 
histological types of prostate cancer.
3. Estimating the relationships between obesity, insulin 
resistance, inflammation and examined adipokines 
in both groups.
Material and methods
Our prospective study was conducted on 140 men 
treated at Urology Hospital UROVITA in Chorzow in 
2014. All subjects who participated in the study gave the 
agreement in the written form. The study was approved 
by the local Ethical Review. Biopsies were performed 
by urologists with transrectal ultrasound.
Depending on the results of histology findings, men 
were divided into two groups: I — prostatic cancer 
(n = 74) and II — with pathologic hyperplasia (n = 66), 
both groups were matched by BMI. 
Exclusion criteria for both groups were: diabetes 
mellitus, heart, renal or liver failures and diagnosis of 
cancer other than prostate cancer. In all men anthropo-
metric measurements were done: BMI was calculated 
as ratio of weight to square of height. Waist circumfer-
ences were measured. Blood samples were obtained in 
the morning time in fasting condition. Serum samples 
were stored frozen in –70oC. In all participants metabolic 
profile was assessed (lipid profile and glucose con-
centrations) using enzymatic method. Serum leptin, 
adiponectin, chemerin and IL-6 concentrations were 
measured by ELISA methods using commercial assays. 
Leptin-to-adiponectin ratio was calculated as leptin in 
ng/mL divided by adiponectin in ug/mL. Serum PSA 
concentrations were assessed using immunochemical 
method (ECLIA). HOMA-I was calculated with for-
mula: HOMA-I = fasting serum glucose concentration 
(mg/dL)/18.1 x fasting serum insulin concentration 
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(uIU/mL)/22.5 [6]. In the current study for diagnosis 
of insulin resistance we have used threshold value 
HOMA-I ≥ 2.5, as other researches [7]. 
Prostate cancer subjects were further subdivided 
according to BMI (values ≤ 25, ≤ 30, and > 30). 
Considering histological differentiation prostate 
cancer patients were then divided into 3 subgroups 
according to the Gleason score: well differentiated 
(Gleason score ≤ 6), moderately differentiated subgroup 
(Gleason 7), and poorly differentiated (Gleason ≥ 8).
Statistical analysis were performed using STATIS-
TICA 12.0, StatSoft Inc. Data were tested for normal 
distribution using W Shapiro-Wilk test. The results are 
presented as mean values with standard deviations and 
medians. Groups were compared by Student`s test or 
U Mann-Whitney test. Correlations between variables 
were estimated by calculating the correlation coeffi-
cient R by Pearson`s method or Spearman`s method. 
The prevalence of obesity and insulin resistance were 
compared using chi-squared test. Logistic regression 
analysis was used to estimated the odds ratios and 
95%CI to evaluate the association between Gleason score 
(Gleason ≤ 6 vs. ≥ 7) and BMI ( < 25 vs. ≥ 25). All results 
were considered as statistically significant with p < 0.05. 
Results
In the first part of the study we have analyzed the data 
from all 140 subjects according to the histological finding 
(group I — cancer, group II — benign hyperplasia). 
The characteristics of men are summarized in Table I.
Statistical analysis showed that mean age of cancer 
group was higher than in hyperplasia group (67.13 ± 
8.48 versus 61.51 ± 10.30). The mean BMI in group I 
was 27.90 ± 3.27 and was similar to group II (27.25 ± 
3.97). There were no differences between groups in 
waist circumference, HOMA-I, serum levels of total 
cholesterol, glucose, triglycerides, adiponectin, leptin 
and chemerin. However, as shown in Table I, the con-
centrations of PSA, IL-6 and leptin-to-adiponectin ratio 
were significantly higher in cancer group compared 
with benign hyperplasia group.
The prevalence of subjects with BMI > 30 did not 
differ between group I and II (24.32%, n = 18 vs. 22.73%, 
n = 15, respectively). The proportions of overweight 
men, defined as 25–30 kg/m2, were also similar (55.45%, 
n = 41 in cancer group, 48.48%, n = 32 in benign pros-
tate hyperplasia group). The proportions of normal BMI 
men (BMI < 25 kg/m2), were similar (20.27%, n = 15 in 
group I, 28.79%, n = 19 in group II). The prevalence of 
insulin resistance was similar in both groups — it was 
recognized in 58%, n = 43 prostate cancer patients and 
in 54.4%, n = 36 benign prostate hyperplasia patients. 
Table II shows the clinical and biochemical characteris-
tics of patients by prostate cancer severity. In the poorly 
differentiated cancer subgroup, subjects were older, had 
higher PSA, leptin, chemerin, IL-6 and triglycerides 
concentrations and higher leptin-to-adiponectin ratio.
Table I. Clinical and biochemical characteristics of men with prostate cancer (group I) and with benign prostate hyperplasia 
(group II)
Tabela I. Kliniczna i biochemiczna charakterystyka mężczyzn z rakiem prostaty = grupa I oraz łagodnym przerostem gruczołu 
krokowego = grupa II
Prostate cancer (group I) 
n = 74
Benign prostate hyperplasia (group II) 
n = 66
P
Age 67.13 ± 8.48 [67.0] 61.51 ± 10.30 [60.0]  < 0.001
BMI [kg/m2] 27.90 ± 3.27 [28.07] 27.25 ± 3.97 [26.68] Ns
Waist [cm] 102.35 ± 9.81 [102.0] 101.77 ± 9.27 [101.0] Ns
Glucose [mg/dL] 104.31 ± 27.97 [102.5] 108.15 ± 33.35 [98.0] Ns
Cholesterol [mg/dL] 186.5 ± 46.91 [184.5] 186.54 ± 45.61 [186.5] Ns
CHDL [mg/dL] 47.24 ± 13.85 [45.0] 50.36 ± 22.47 [47.5] Ns
Triglycerides [mg/dL] 124.49 ± 49.09 [115.0] 138.12 ± 91.32 [111.0] Ns
HOMA-I 3.94 ± 4.27 [3.28] 5.32 ± 8.19 [3.07] Ns
Adiponectin [ug/mL] 18.28 ± 8.08 [16.0] 17.83 ± 8.63 [16.32] Ns
Leptin [ng/mL] 9.79 ± 8.27 [7.87] 9.03 ± 7.26 [7.82] Ns
Leptin-to-adiponectin ratio 0.68 ± 0.70 [0.49] 0.64 ± 0.60 [0.46]  < 0.05
Chemerin [ng/mL] 273.48 ± 78.81 [268.7] 267.98 ± 83.46 [253.3] Ns
IL-6 [pg/mL] 17.30 ± 31.14 [7.23] 11.75 ± 20.66 [4.24]  < 0.01
PSA [ng/mL] 33.71 ± 89.82 [8.0] 3.74 ± 5.41 [1.48]  < 0.001
Data were given as mean ± SD, and median. Groups were compared by Student`s test or U Mann-Whitney test
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Then logistic regression analysis was performed to 
calculate odds ratio (OR) for the presence of moderately 
and poorly differentiated PC (Gleason score ≥ 7). Cases 
with BMI ≥ 25 tended to have higher Gleason score. 
Odds ratio for subjects with BMI ≥ 25 was 3.11 (95% 
confidence interval CI 1.01-9.52). 
In the next step of the study we assessed the cor-
relations of serum adipokines with analyzed variables 
in all participants, as well as in both groups separately 
(Table III). 
In the all men serum adiponectin was significantly 
correlated with HOMA-I, BMI, glucose, triglycerides, 
cHDL (Table III). There were strong significant correla-
tions between leptin and BMI, HOMA-I, waist, glucose, 
triglycerides and cHDL. Among all the participants we 
observed associations between chemerin and waist 
as well as triglycerides. In prostate cancer patients 
chemerin correlated also with IL-6 (R = 0.17, p < 0.05) 
and leptin (R = 0.22, p < 0.01) — Figure I. We also 
measured a significant positive correlation between 
serum chemerin and Gleason score (R = 0.32, p < 0.01), 
as well as between serum leptin and Gleason score 
(R = 0.20, p < 0.05). There was a positive correlation 
between adiponectin and PSA levels in all men (R = 0.32, 
P < 0.001), as well as in cancer group (R = 0.27, p < 0.01).
Discussion
Obesity is associated with increased risk of various 
cancers including: breast, renal, colon, corpus uteri 
and prostate [2, 8]. It is estimated that in 2012 about 
3.6 % of all new cases of cancer in adults can be at-
tributed to high BMI [9]. There is a gradual increase 
of prostate cancer incidence, especially in developed 
countries, according to increasingly Western eating 
abits. Accumulating evidences suggest that visceral 
obesity is associated with higher risk of progression 
and recurrence of prostate cancer [10, 11]. However, 
several studies have given contradictory results and 
have failed to confirm the associations between greater 
BMI and worse prostate cancer prognosis [12, 13]. Our 
results are concordant with previous studies which 
determined that obesity is associated with higher ag-
gressiveness. In our study the association between BMI 
and prostate cancer upgrading based on Gleason sum 
has been revealed. We have found that overweight 
and obese men with prostate cancer were three times 
more likely to have Gleason score ≥ 7 than those with 
normal BMI. Of note, this study was not conducted 
among random population because the studied group 
included men from Silesian population, which is 
Table II. The clinical and biochemical characteristics of patients by prostate cancer severity
Tabela II. Charakterystyka kliniczno-biochemiczna pacjentów z rakiem prostaty w zależności do nasilenia procesu 
nowotworowego
Well differentiated prostate cancer 
subgroup (Gleason score ≤ 6, n = 24),
Moderately differentiated cancer 
subgroup (Gleason 7, n = 28)
Poorly differentiated cancer  
subgroup (Gleason ≥ 8, n = 22)
Age 64.62 ± 8.49 [65.6] 66.75 ± 8.75 [66.5] 70.24 ± 7.53 [68.0]*
BMI [kg/m2] 27.19 ± 3.62 [27.12] 28.04 ± 2.81 [27.08] 28.32 ± 3.38 [28.10]
Waist [cm] 101.42 ± 9.30 [100.50] 101.32 ± 9.75 [100.50] 104.09 ± 10.32 [104.00]
Glucose [mg/dL] 107.29 ± 41.56 [104.0] 103.86 ± 21.51 [101.0] 99.52 ± 11.12 [103.0]
Cholesterol [mg/dL] 170.12 ± 51.53 [165.5] 199.25 ± 46.86 [202.0] 188.95 ± 38.03 [184.0]
CHDL [mg/dL] 48.79 ± 12.56 [51.5] 47.28 ± 16.31 [42.5] 45.52 ± 12.38 [43.0]
Triglycerides [mg/dL] 113.79 ± 47.60 [98.0] 122.82 ± 29.81 [117.5] 136.81 ± 67.74 [116.0]*
HOMA-I 3.28 ± 2.31 [2.64] 4.63 ± 6.22 [3.51] 3.69 ± 2.52 [3.09]
Adiponectin [ug/mL] 17.53 ± 8.35 [16.0] 19.13 ± 9.19 [16.29] 18.29 ± 6.28 [17.0]
Leptin [ng/mL] 7.73 ± 7.01 [5.65] 8.98 ± 6.10 [8.33] 13.34 ± 11.20 [9.69]*
Leptin-to-adiponectin ratio 0.46 ± 0.29 [0.30] 0.64 ± 0.54 [0.52] ^ 0.85 ± 0.87 [0.63]***&
Chemerin [ng/mL] 237.44 ± 72.43 [238.55] 273.94 ± 59.91 [262.35] ^ 312.80 ± 92.60 [286.6]** &
PSA [ng/mL] 16.21 ± 41.22 [5.61] 16.56 ± 27.72 [6.82] 76.94 ± 152.75 [19.0]*** &
IL-6 15.78 ± 19.87 [7.63] 17.91 ± 29.03 [8.71]^ 18.88 ± 44.56 [6.33]*
Data were given as mean ± SD, and median. Groups were compared by Student`s test or U Mann-Whitney test
*P < 0.05 — poorly differentiated cancer subgroup vs well differentiated prostate cancer subgroup 
**P < 0.01 — poorly differentiated cancer subgroup vs well differentiated prostate cancer subgroup 
***P < 0.001 — poorly differentiated cancer subgroup vs well differentiated prostate cancer subgroup 
^P < 0.05 — moderately differentiated cancer subgroup vs well differentiated prostate cancer subgroup 
&P < 0.05 — poorly differentiated cancer subgroup vs moderately differentiated cancer subgroup 
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characterized by growing percentage of obesity dur-
ing the last time [14]. It might significantly affect the 
obtained results.
Obesity may influence prostate cancer develop-
ment and aggressiveness in various ways. One of the 
mechanisms linking obesity and cancerogenesis may 
be adipose tissue dysfunction with altered adipokines 
secretion and persistent inflammation [15]. Another 
potential factor to explain the link between obesity 
and cancer is hyperinsulinemia and increased IGF-I 
response to GH [16]. In this study we have focused on 
the serum concentrations of adipokines which concen-
trations are related to the adiposity: leptin, adiponectin 
and chemerin. Indeed, in our study we have observed 
correlations between adipokines and BMI, waist cir-
cumferences and different parameters of metabolic 
profile such as glucose, triglycerides and cHDL. 
Table III. Correlations of adipokines: adiponectin, leptin and chemerin with selected anthropometric and biochemical variables 
in all men, in prostate cancer and in benign prostate hyperplasia patients
Tabela III. Korelacje pomiędzy stężeniem adiponektyny, leptyny i chemeryny oraz wybranych parametrów antropometrycznych 
i biochemicznych u wszystkich badanych, z rakiem prostaty i z łagodnym przerostem gruczołu krokowego 
Correlations between HOMA index and serum concentrations of adipokines
Leptin Adiponectin Chemerin
All the participants R = 0.47, p < 0.001 R = –0.29. p < 0.001 R = 0.13, p = NS
Prostate cancer R = 0.53, p < 0.001 R = –0.23, p = 0.05 R = 0.15, p = NS
Prostate hypertrophia R = 0.40, p < 0.001 R = –0.36, p < 0.01 R = 0.10, p = NS
Correlations between BMI and serum concentrations of adipokines
All the participants R = 0.55, p < 0.001 R = –0.11, p = NS R = 0.11, p = NS
Prostate cancer R = 0.38, p < 0.001 R = –0.26, p = 0.02 R = 0.19, p = 0.05
Prostate hypertrophia R = 0.74, p < 0.001 R = 0.08, p = NS R = –0.03, p = NS
Correlations between waist circumference and serum concentrations of adipokines
All the participants R = 0.54, p < 0.001 R = –0.05, p = NS R = 0.19, p < 0.01
Prostate cancer R = 0.46, p < 0.001 R = –0.23, p < 0.05 R = 0.17, p < 0.05
Prostate hypertrophia R = 0.28, p < 0.01 R = –0.14, p = NS R = 0.04, p = NS
Correlations between serum concentrations of IL–6 and adipokines
All the participants R = 0.10, p = NS R = –0.04, p = NS R = 0.13, p = NS
Prostate cancer R = 0.14, p < 0.05 R = –0.01, p = NS R = 0.17, p < 0.05
Prostate hypertrophia R = 0.24, p < 0.05 R = –0.08, p = NS R = 0.03, p = NS
Correlations between serum concentrations of glucose and adipokines
All the participants R = 0.29, p < 0.001 R = –0.16, p = NS R = 0.07, p = NS
Prostate cancer R = 0.24, p < 0.05 R = –0.10, p = NS R = 0.15, p = NS
Prostate hypertrophia R = 0.33, p < 0.01 R = –0.24, p < 0.05 R = 0.03, p = NS
Correlations between serum concentrations of cHDL and adipokines
All the participants R = 0.03, p = NS R = 0.27, p < 0.01 R = –0.15, p = NS
Prostate cancer R = 0.06, p = NS R = 0.19, p = NS R = –0.17, p = NS
Prostate hypertrophia R = 0.01, p = NS R = 0.34, p < 0.01 R = –0.10, p = NS
Correlations between serum concentrations of triglycerides and adipokines
All the participants R = 0.17, p < 0.05 R = –0.28, p < 0.001 R = 0.25, p < 0.01
Prostate cancer R = 0.27, p < 0.05 R = –0.28, p < 0.01 R = 0.37, p < 0.001
Prostate hypertrophia R = 0.10, p = NS R = –0.29, p < 0.01 R = 0.12, p = NS
Figure I. Correlations between serum leptin and chemerin in men 
with prostate cancer
Rycina I. Korelacje pomiędzy stężeniem leptyny i chemeryny 
u mężczyzn z rakiem prostaty
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Leptin concentrations are increased in obese pa-
tients and it is well documented that this hormone 
stimulates tumor cells growth and invasion. There is 
a growing evidence of its role in development of colo-
rectal, hepatocellular, breast and thyroid cancer [17]. 
Observation that leptin receptors have high expression 
in the prostate proves leptin role in pathophysiology 
processes [18]. Different studies have evaluated a role 
of leptin in the pathogenesis of prostate cancer but the 
results are contradictory. Some authors reported that 
hyperleptinemia is associated with increased risk for 
prostate cancer [19, 20], but recently published data 
about this subject are inconsistent [21, 22]. In this study 
we have found that serum leptin levels were similar 
in prostate cancer and benign hyperplasia patients. 
However, subjects with poorly differentiated cancer 
had higher leptin levels than patients with well differ-
entiated cancer. Our results are in agreement with the 
previously published data [23]. This association could be 
explained considering that hyperleptynemia promotes 
neoangiogenesis and prostate cancer cells proliferation. 
In our study leptin were correlated with IL-6 and with 
insulin resistance in both groups, however only in the 
cancer group we have demonstrated relationships 
between leptin and chemerin and between IL-6 and 
chemerin. It is possible that leptin interacts with other 
hormones and cytokines and the crosstalking between 
them fosters cancerogenesis and invasion. 
In this study we have observed that prostate cancer 
men exhibit elevated serum IL-6 concentrations when 
compared with benign prostate hyperplasia men. Our 
finding are in agreement with those obtained by other 
researchers [24, 25]. Increased levels of this inflammatory 
cytokine modulate the expression of genes responsible 
for cell proliferation and angiogenesis via the JAK-STAT 
signaling pathway. Shariat et al described that increased 
inflammatory cytokines concentrations might be in-
volved in prostate cancer aggressiveness [25]. In this 
study we have observed higher IL-6 levels in poorly dif-
ferentiated cancer subgroup than in well differentiated 
prostate cancer subgroup and we have demonstrated 
relationships between IL-6 and chemerin which also 
was connected with prostate cancer aggressiveness. It is 
possible that chronic inflammation which is associated 
with disturbed adipokine secretion and signaling, fosters 
prostate cancer development and growth. 
Reduced serum adiponectin has been seen in 
a number of different cancers such as oesophageal, 
gastric, pancreatic, colorectal, hepatic, breast, endome-
trial cancer, lung and renal [26]. In our study we didn't 
observe the differences in serum adiponectin between 
prostate cancer and benign prostate hyperplasia and 
we didn`t demonstrate correlations with Gleason score, 
which was postulated by some researchers [27–29]. 
Results of studies examined relationships between 
serum adiponectin and prostate cancer are contradic-
tory. AdipoR1 and AdipoR2 have been identified on 
both benign and malignant human prostate cells [30]. 
However, the epithelium of malignant prostatic glands 
showed an enhanced adiponectin expression in com-
parison with benign hyperplasia [30]. In vitro studies 
have demonstrated that adiponectin exerts effects on 
prostate cancer cells by modulating AMPK and PI3 
kinase/Akt pathways [31]. Series studies have reported 
that patients with prostate cancer exhibited decreased 
serum adiponectin concentrations as compared in 
men with benign prostate cancer or in healthy controls 
[27–29]. Moreover, adiponectin was significantly and in-
versely connected with prostate stage or Gleason score 
[28]. Some authors described inverse associations only 
in overweight or obese men, but not in normal weight 
or in all men [32]. However, few studies are consistent 
with our observations and have excluded the potential 
relations between low adiponectin concentration and 
prostate cancer risk [22, 30, 33]. In this study, adiponec-
tin concentrations have reflected mainly metabolic 
status and have correlated with HOMA-I, cHDL and 
triglycerides levels in both cancer and benign hyperpla-
sia groups. Furthermore, in cancer group adiponectin 
was connected with BMI and waist circumference. 
Besides, in all men and in the cancer group we have 
found significant correlations between adiponectin 
and PSA concentrations. Our results are in agreement 
with results of the study by Ikeda et al. who also have 
found the significant associations between adiponectin 
and PSA in almost 3000 Japanese men [34]. However, 
nature of those dependencies is unknown and there is 
a need for further clinical and experimental studies to 
resolve the nature of those relationships.
Although we didn`t detect significant differences in 
adiponectin or leptin levels, we have manifested signifi-
cantly larger leptin-to-adiponectin ratio in cancer men 
in comparison to benign hyperplasia group. To the best 
of our knowledge this is the first study in which higher 
ratio was detected in prostate cancer men, regardless of 
anthropometric parameters. Although Tewari et al. have 
observed higher proportion between high leptin and 
low adiponectin in prostate cancer group, they have 
obtained results which were depended on different 
nutritional status of studied groups [35]. In the poorly 
differentiated cancer subgroup, subjects had higher 
leptin-to-adiponectin ratio. It is assumed that leptin-
to-adiponectin index represents more precise marker 
of adipose tissue dysfunction [36]. It suggests that not 
isolated adipokines are critical in the development of 
prostate cancer but imbalance between leptin and adi-
ponectin may be a crucial moment in cancerogenesis 
and aggressiveness. 
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Chemerin is an adipokine expressed and secreted 
predominantly by adipocytes which is associated with 
obesity and metabolic syndrome. This adipokine is 
involved in metabolism and immune reactions. Re-
cently, the potential role of chemerin in cancerogenesis 
was described [37, 38]. Higher chemerin levels were 
observed in non-small cell lung cancer patients com-
pared with healthy controls and were associated with 
advanced TNM stage [37]. Elevated serum levels of 
chemerin were also determined in gastric cancer and 
colorectal cancer patients [38]. To our knowledge, the 
relationship between chemerin and prostate cancer 
has not been investigated previously. Therefore, we 
assessed chemerin levels in prostate cancer men and 
compared with patients with diagnosed benign pro-
static hyperplasia but we didn`t find the differences 
between groups. However, after subdividing prostate 
cancer group considering the Gleason score, it was 
found that chemerin concentrations has grown simul-
taneously with prostate cancer severity. Further studies 
are needed to explain the mechanism underlying this 
increase. It should be noted that in the cancer group 
the chemerin concentrations positively correlated with 
leptin, IL-6 levels and leptin-to-adiponectin ratio. In 
addition, chemerin levels were affected by nutritional 
status, as chemerin concentrations were proportional 
to BMI, waist circumferences and triglycerides levels. 
It is possible that cluster of adipokines and cytokines 
perturbation may contribute to cancerogenesis and 
aggressiveness of prostate cancer. 
In summary, leptin-to-adiponectin ratio and IL-6 
were elevated in men with prostate cancer. Leptin, 
chemerin, IL-6 and leptin-to-adiponectin ratio were as-
sociated with Gleason score but the relationships were 
dependent on each other. Overweight and obese men 
with prostate cancer were more likely to have moder-
ately differentiated or poorly differentiated cancer than 
those with normal BMI.
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